How did ATYR's Q1 2024 EPS surprise impact its stock?

ATYR's Q1 2024 EPS surprise did not impact its stock as there is no available data on the EPS surprise for this quarter. However, we can analyze the impact of its Q4 2023 EPS miss on its stock. 1. **Q4 2023 EPS Miss**: aTyr Pharma missed the estimated EPS by -4.0%, reporting an EPS of -$0.25 versus an estimate of -$0.24. This indicates a wider miss than the previous quarter's EPS miss. 2. **Stock Reaction to Q4 2023 EPS Miss**: The stock's reaction to the Q4 2023 EPS miss is not directly documented. However, it is known that aTyr Pharma experienced a 3.0% drop in its share price following the earnings release in the previous quarter after beating EPS estimates by $0.03. 3. **Investor Sentiment**: Given the trend of investor sentiment based on past performance, it is likely that the stock may have experienced a negative reaction to the Q4 2023 EPS miss, although the exact percentage change is not available. In conclusion, while we don't have specific data on the impact of the Q1 2024 EPS surprise, historical trends suggest that aTyr Pharma's stock may have been negatively affected by the EPS miss, as was the case with the Q4 2023 EPS miss.